Cytokinetics ceo

WebApr 3, 2024 · Despite these results, Cytokinetics drew out some positive signals of efficacy from a post hoc analysis of the data. After consulting with the FDA, the company decided to push through with a Phase III study of reldesemtiv, Robert Blum, president and CEO, Cytokinetics, told BioSpace in an email. WebApr 10, 2024 · SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 22 nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2024 at 10:00 …

Cytokinetics CEO: Why It

WebMay 7, 2024 · Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Diane Weiser – Senior Vice … WebMar 31, 2024 · Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis. Cytokinetics to Host Conference Call and Webcast Today at 8:30 am Eastern Time. SOUTH SAN FRANCISCO, Calif., March 31, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Data Monitoring … on the vine sprouts https://southpacmedia.com

RTW Investments, LP, Ji Xing Pharmaceuticals and Cytokinetics …

WebCytokinetics. We are developing potential medicines to improve the healthspan of people with devastating cardiovascular and … WebMar 31, 2024 · The company in the coming months will assess measures needed for the development of its neuromuscular pipeline, Cytokinetics CEO Robert Blum said in a statement. ALS, also known as Lou Gehrig’s disease, breaks down nerve cells in the brain and spinal cord that make muscles work, leading to progressive paralysis and death. ... WebCytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, ... In January 2007, Cytokinetics named Robert I. Blum as president and CEO. Prior to this, Blum has been involved in the company since its founding, ... ios fastclick

Cytokinetics (Nasdaq:CYTK) - Stock Price, News & Analysis

Category:Cytokinetics CEO And Leadership: Executives and …

Tags:Cytokinetics ceo

Cytokinetics ceo

Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert I. Blum …

WebMar 31, 2024 · Cytokinetics’ ALS research has revolved around “troponin,” a protein involved in muscle movement, with the idea being that activating this protein may help treat the disease. The company’s first attempt at this resulted in an experimental medicine called tirasemtiv, but it was shelved after missing the primary goal of a late-stage study ... WebAug 12, 2024 · August 12th, 2024, 1:08 PM PDT. Robert Blum, President and CEO at Cytokinetics discusses his company outlook. He speaks with David Ingles on "Bloomberg Daybreak: Asia". (Source: Bloomberg)

Cytokinetics ceo

Did you know?

WebNov 18, 2024 · Based on our data team's research, Robert I. Blum is the Cytokinetics's CEO. Cytokinetics has 130 employees, of which 42 are in a leadership position. Here are … WebOct 22, 2024 · Robert Blum became the CEO of Cytokinetics, Incorporated ( NASDAQ:CYTK) in 2007, and we think it's a good time to look at the executive's …

WebNov 10, 2024 · In 2007, I became both President and CEO.” Cytokinetics is a leader in a specific area of biology focused on the discovery, development and commercialization of new medicines that modulate the mechanics of … WebMar 31, 2024 · SOUTH SAN FRANCISCO, Calif. , April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, …

WebJan 2024 - Mar 20243 years 3 months. San Francisco Bay Area. Accountable for leading Development Operations to ensure timely … WebJul 14, 2024 · Cytokinetics President and CEO, Robert I. Blum, said: “We are pleased to enter into these transactions with RTW and Ji Xing to both accelerate and expand the development of CK-274 in cardiovascular diseases associated with hypercontractility,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. ...

WebApr 13, 2024 · In other Cytokinetics news, CEO Robert I. Blum sold 12,500 shares of the company’s stock in a transaction on Tuesday, March 28th. The stock was sold at an average price of $35.05, for a total transaction of $438,125.00. Following the completion of the sale, the chief executive officer now owns 441,058 shares in the company, valued at ...

WebOct 27, 2024 · Cytokinetics CEO: Why It's OK Not Being An Overnight Success Licensing ALLISON GATLIN 05:02 PM ET 10/27/2024 Nobody will accuse Cytokinetics ( CYTK) … on the vine tomatoes nutrition factsWebCytokinetics's President, Chief Executive Officer and Director is Robert I Blum. Other executives include Daniel R Casper, Vice President, Information Technology; Andrew … ios family sharing photosWebDec 27, 2024 · Cytokinetics has been finding treatments for muscle weakening conditions such as ALS for 20 years. President and CEO … on the vine scarborough meWebFeb 21, 2024 · The estimated net worth of Robert I. Blum is at least $17.05 million as of January 17th, 2024. Mr. Blum owns 406,412 shares of Cytokinetics stock worth more than $17,048,983 as of March 4th. This net worth evaluation does not reflect any other investments that Mr. Blum may own. Learn More about Robert I. Blum's net worth. ios fastcompanyWebApr 12, 2024 · Cytokinetics, Incorporated has a 1 year low of $32.96 and a 1 year high of $55.80. Cytokinetics (NASDAQ:CYTK – Get Rating) last posted its earnings results on Wednesday, March 1st. The ... on the vine tomatoWebNov 10, 2024 · Robert hopes Cytokinetics will be remembered as a company that ensures patients have equitable access to the medicines that it’s developing, as well as for being a truly innovative organization that … on the vine st john nbon the vine weekly flyer saint john nb